Literature DB >> 30336225

Imatinib stimulates prostaglandin E2 and attenuates cytokine release via EP4 receptor activation.

Thomas Bärnthaler1, Katharina Jandl2, Heinz Sill3, Barbara Uhl3, Yannick Schreiber4, Magdalena Grill1, Dominique Thomas5, Rudolf Schicho6, Gunther Marsche6, Saša Frank7, Akos Heinemann6, Rufina Schuligoi8.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30336225     DOI： 10.1016/j.jaci.2018.09.030

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN： 0091-6749            Impact factor:   10.793


× No keyword cloud information.
  6 in total

1.  International Union of Basic and Clinical Pharmacology. CIX. Differences and Similarities between Human and Rodent Prostaglandin E2 Receptors (EP1-4) and Prostacyclin Receptor (IP): Specific Roles in Pathophysiologic Conditions.

Authors:  Xavier Norel; Yukihiko Sugimoto; Gulsev Ozen; Heba Abdelazeem; Yasmine Amgoud; Amel Bouhadoun; Wesam Bassiouni; Marie Goepp; Salma Mani; Hasanga D Manikpurage; Amira Senbel; Dan Longrois; Akos Heinemann; Chengcan Yao; Lucie H Clapp
Journal:  Pharmacol Rev       Date:  2020-10       Impact factor: 25.468

2.  Inhibition of mPGES-1 attenuates efficient resolution of acute inflammation by enhancing CX3CL1 expression.

Authors:  Bernhard Brüne; Tobias Schmid; Peter Rappl; Silvia Rösser; Patrick Maul; Rebekka Bauer; Arnaud Huard; Yannick Schreiber; Dominique Thomas; Gerd Geisslinger; Per-Johan Jakobsson; Andreas Weigert
Journal:  Cell Death Dis       Date:  2021-02-02       Impact factor: 8.469

3.  Monocytes and Macrophages Serve as Potent Prostaglandin D2 Sources during Acute, Non-Allergic Pulmonary Inflammation.

Authors:  Sonja Rittchen; Katharina Jandl; Ilse Lanz; Bernhard Reiter; Nerea Ferreirós; Daniel Kratz; Jörg Lindenmann; Luka Brcic; Thomas Bärnthaler; Reham Atallah; Horst Olschewski; Eva M Sturm; Akos Heinemann
Journal:  Int J Mol Sci       Date:  2021-10-28       Impact factor: 5.923

4.  Immunomodulation and endothelial barrier protection mediate the association between oral imatinib and mortality in hospitalised COVID-19 patients.

Authors:  Justin de Brabander; Erik Duijvelaar; Job R Schippers; Patrick J Smeele; Hessel Peters-Sengers; Jan Willem Duitman; Jurjan Aman; Harm J Bogaard; Tom van der Poll; Lieuwe D J Bos
Journal:  Eur Respir J       Date:  2022-07-26       Impact factor: 33.795

5.  Imatinib might constitute a treatment option for lung involvement in COVID-19.

Authors:  David Bernal-Bello; Beatriz Jaenes-Barrios; Alejandro Morales-Ortega; José Manuel Ruiz-Giardin; Virginia García-Bermúdez; Begoña Frutos-Pérez; Ana Isabel Farfán-Sedano; Cristina de Ancos-Aracil; Fernando Bermejo; Mario García-Gil; Antonio Zapatero-Gaviria; Juan Víctor San Martín-López
Journal:  Autoimmun Rev       Date:  2020-05-03       Impact factor: 9.754

Review 6.  NF-κB Signaling and Inflammation-Drug Repurposing to Treat Inflammatory Disorders?

Authors:  Annabell Roberti; Laura Elizabeth Chaffey; David R Greaves
Journal:  Biology (Basel)       Date:  2022-02-26
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.